Pharma & Fine Chemicals: Market Briefs

September 1999
Chemical Market Reporter;09/20/99, Vol. 256 Issue 12, p12
Trade Publication
Presents news briefs from the pharmaceuticals and fine chemicals industries as of September 20, 1999. Acquisition of marketing and distribution rights for Sanofi-Sythelabo's Dynabac in the United States by Muro Pharmaceutical Inc.; Marketing approval received by Nordisk AS for its liquid growth hormone, Norditropin SimpleXx; Approval of Ferring Pharmaceuticals' drug application for Repronex, a fertility drug.


Related Articles

  • NEW STORAGE GUIDELINES.  // Drug Topics;2/6/2006, Vol. 150 Issue 3, p52 

    The article reports that Princeton, New Jersey-based Novo Nordisk AS has received new storage guidelines approved by the U.S. Food and Drug Administration. The new storage guidelines are intended for the company's 5- and 10-milligram Norditropin NordiFlex prefilled multi-dose disposable growth...

  • NEW DEVICES.  // Drug Topics;2/6/2006, Vol. 150 Issue 3, p55 

    The article announces the addition of the 10-milligram pen to the line of Norditropin Nordiflex 5-milligram and 10-milligram pens from Novo Nordisk AS in Princeton, New Jersey. The new container size will allow physicians to more closely calculate doses of growth hormone based on weight and age,...

  • Danish drug company buys Indian products.  // Nature;3/6/1997, Vol. 386 Issue 6620, p10 

    Discusses the significance of Danish pharmaceutical company Novo Nordisk's buying of the rights to develop and market products made by Dr. Reddy's Research Foundation, which is based in India. The types of products usually associated with the two organizations.

  • NEW INDICATIONS.  // Drug Topics;7/9/2007, Vol. 151 Issue 13, p42 

    The article evaluates the Norditropin Injection somatotropin from Novo Nordisk.

  • Novo files growth hormone patent infringement suit in US.  // Chemical Market Reporter;10/13/97, Vol. 252 Issue 15, p24 

    Discloses that Novo Nordisk A/S has filed a patent infringement lawsuit in a US District Court against four companies that manufacture and/or market biosynthetic human growth hormones that compete with Novo Nordisk's product in the United States. List of companies cited in the lawsuit; Details...

  • Novo Nordisk to market human growth hormone.  // Drug Topics;1/6/97, Vol. 141 Issue 1, p10 

    Reports on a United States Court of Appeals' decision allowing Novo Nordisk AS to market its recombinant human growth hormone, Norditropin.

  • Modular award.  // Process Engineering;May2005, Vol. 86 Issue 5, p6 

    Reports that Novo Nordisk AS newest pharmaceutical manufacturing facility in Hillerø Denmark was named as the winner of the 2005 Facility of the Year award by the ISPE conference and the U.S. magazine "Pharmaceutical Processing." Use of a modular engineering concept in the construction of the...

  • Novo Nordisk Cancels Clinical Trials. Houlton, Sarah // Pharmaceutical Executive;Sep2002, Vol. 22 Issue 9, p28 

    Reports on Denmark-based Novo Nordisk's decision to suspend its clinical trials for the dual-acting insulin sensitizer, ragaglitazar. Adverse impact of the company's decision on its share price; Potential of ragaglitazar as a blood glucose regulator.

  • Knowing Its Niche. Sorensen, Lars; Nordisk, Novo // Pharmaceutical Executive;Oct99, Vol. 19 Issue 10, p44 

    Profiles Lars Rebien Sorensen, executive vice-president in charge of health care business of Novo Nordisk of Denmark company. Medicine pioneered by the company; Educational and professional background on Sorensen; Background of the company; Expansion plans of the company; Marketing strategy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics